Vasohibin-1重组腺病毒对人卵巢癌SKOV-3细胞增殖的影响  

Effects of Vasohibin-1 Recombinant Adenovirus on Proliferation of Human Ovarian Cancer SKOV-3 Cells

作　　者：李荣[1,2] 吴裕中[1,2] 吴强[1,2] 

机构地区：[1]南京医科大学附属肿瘤医院 [2]江苏省肿瘤医院,江苏南京210009

出　　处：《肿瘤学杂志》2014年第1期1-5,共5页Journal of Chinese Oncology

基　　金：江苏省科技厅社会发展项目资助课题(BS2006072;BS2002058);江苏省中医药局课题(LZ13234;H07029);江苏省肿瘤医院课题(ZS201202;ZM201103)

摘　　要：[目的]研究内源性血管生成抑制因子vasobihin-1对人卵巢癌SKOV-3细胞体外增殖能力的影响。[方法]体外培养SKOV-3细胞,用vasohibin-1重组腺病毒感染SKOV-3细胞,采用蛋白质印迹法检测SKOV-3细胞中vasohibin-1蛋白的表达水平,应用CCK-8法检测不同时间点vasohibin-1重组腺病毒对SKOV-3细胞增殖的抑制能力。[结果]感染48h后,在SKOV-3细胞中vasohibin-1蛋白表达量与对照组相比显著性增加(P<0.05);25MOI vasohibin-1重组腺病毒感染SKOV-3细胞24h时,过表达组与阴性对照相比,两者之间没有统计学差异(P=0.065);余各组间相比差异均具有统计学意义(P<0.05),且抑制能力随MOI增大而增加(P<0.05),随时间的延长而增加(P<0.05)。[结论]Vasohibin-1过表达能够抑制SKOV-3细胞的增殖能力,并具有浓度和时间依赖性,可为卵巢癌的治疗提供新思路。[Purpose] To investigate the effects of the endogenous angiogenesis inhibitor vaso- hibin-1 on proliferation of the human ovarian cancer SKOV-3 cells. [Methods] SKOV-3 cells were cultured in vitro,then transfected by vasohibin-1 recombinant adenovirus. The expression of vasohibin-1 protein in SKOV-3 cells was confirmed by Western blot. The inhibition of prolif- eration in SKOV-3 cells were estimated by CCKg in different times. [Results]Compared with control group,the expression of vasohibin-1 protein increased significantly after transfection for 48h（P〈0.05）.There was no statistical difference between overexpression group and negative con- trol group after 25MOI vasohibin-1 recombinant adenovirus transfected SKOV-3 cells for 24h （P=0.065） ;but the other groups had statistical significance and the inhibition of vasohibin-1 re- combinant adenovirus on the proliferation of SKOV-3 cells increased with the growth of MOI and with the time prolonging（P〈0.05）. [Conclusion~ Overexpression of vasohibin-1 could inhibit the proliferation of SKOV-3 cells,with dose- and time- dependent manners,which may provide a new idea for ovarian cancer treatment.

关 键 词：SKOV-3细胞 重组腺病毒 细胞增殖 人卵巢癌 VASOHIBIN 内源性血管生成抑制因子 蛋白质印迹法 腺病毒感染 

分 类 号：R737.31[医药卫生—肿瘤]